Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Allogene Therapeutics (ALLO) Invested Capital: 2019-2025

Historic Invested Capital for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $315.3 million.

  • Allogene Therapeutics' Invested Capital fell 32.00% to $315.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $315.3 million, marking a year-over-year decrease of 32.00%. This contributed to the annual value of $422.2 million for FY2024, which is 17.58% down from last year.
  • As of Q3 2025, Allogene Therapeutics' Invested Capital stood at $315.3 million, which was down 8.48% from $344.6 million recorded in Q2 2025.
  • Allogene Therapeutics' Invested Capital's 5-year high stood at $1.1 billion during Q1 2021, with a 5-year trough of $315.3 million in Q3 2025.
  • Moreover, its 3-year median value for Invested Capital was $463.7 million (2024), whereas its average is $474.0 million.
  • Per our database at Business Quant, Allogene Therapeutics' Invested Capital soared by 76.38% in 2021 and then slumped by 33.10% in 2025.
  • Over the past 5 years, Allogene Therapeutics' Invested Capital (Quarterly) stood at $925.2 million in 2021, then dropped by 27.92% to $666.9 million in 2022, then dropped by 23.19% to $512.2 million in 2023, then fell by 17.58% to $422.2 million in 2024, then slumped by 32.00% to $315.3 million in 2025.
  • Its Invested Capital stands at $315.3 million for Q3 2025, versus $344.6 million for Q2 2025 and $385.4 million for Q1 2025.